

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

[Translation]

March 22, 2022

To: Shareholders

Company Name: Renascience Inc.

Name of Representative: Koji Naito, President & CEO

(Code: 4889 TSE Mothers)

Inquiries: Kazuhiro Ikeda, Director, CFO

**Announcement of the Adoption of the Project under AMED Research
Program of “Practical Application of Innovative Cancer Therapy” in
FY2022**

The Japan Agency for Medical Research and Development (AMED) adopted the Project, under the Research Program of the "Practical Application for Innovative Cancer Therapy" in fiscal 2022, that was applied by Tohoku University, and the Company will participate in the Project as a sharing research organization.

Particulars

1. Adopted Project

Name of the Research Program: "Practical Application of Innovative Cancer Therapy" in fiscal 2022

Research Area : 3-2 Investigator-initiated clinical trials for the development and regulatory approval of innovative cancer drugs (pharmaceuticals)

Name of the Project: A phase III study for chronic myeloid leukemia to evaluate the safety and efficacy of TM5614 in long-term use in combination with tyrosine kinase inhibitors

(Principal Investigator: Professor Hideo Harigae, Tohoku University Graduate School of Medicine)

Subject assigned to the Company: Storage, Transport, and Management of the Investigational New Drugs

In this Project, Tohoku University will conduct an investigator-initiated clinical trial (a phase III trial) aiming for regulatory approval of RS5614 (TM5614) with a research grant from AMED. The Company will receive a portion of the research grant obtained by Tohoku University to manufacture, store, and manage the active pharmaceutical ingredient and the investigational drug product to be used in the study, and will provide (transport) the investigational drug to the sites where the study is conducted. In addition, the Company will provide its GLP non-clinical study data, clinical trial data, knowledge, and know-how to the Project.

2. Outlook for the future

There will be no change to the earnings forecast for the fiscal year ending March 31, 2022 as a result of this matter. The impact on the full-year results for the fiscal year ending March 31, 2023, which will be incorporated into the earnings forecast for the fiscal year ending March 31, 2023 to be announced in the future, is expected to be negligible.

End